Development and validation of a stability-indicating HPLC method for the simultaneous determination of Losartan potassium, hydrochlorothiazide, and their degradation products
Deanne L. Hertzog a,*, Jennifer Finnegan McCafferty b , Xueguang Fang b , R. Jeffrey Tyrrell c , Robert A. ReednJournal of Pharmaceutical and Biomedical Analysis 30 (2002) 747u2013760
An Efficient, Commercially Viable, and Safe Process for Preparation of Losartan Potassium, an Angiotensin II Receptor Antagonist
, Jennifer Finnegan McCafferty b , Xueguang Fang b , R. Jeffrey Tyrrell c , Robert A. Reed – Journal of Pharmaceutical and Biomedical Analysis 30 (2002) 747–760
![2’-(2H-Tetrazol-5-yl)-[1,1’-biphenyl]-4-carboxaldehyde](https://alentris.org/wp-content/uploads/ALN-L028024-1.png)
![4′-methyl-[1,1′-biphenyl]-2-carbonitrile](https://alentris.org/wp-content/uploads/ALN-L028023-1.png)
